Dihydromyricetin vs Myricetin: The Structural Relationship and Formulation Guide

Written and reviewed by Dr. Xiaoyan Qiu · July 2026

One Reduction Step, Two Different Ingredients

Dihydromyricetin (DHM) and myricetin are structurally related — DHM is literally the dihydro-reduced form of myricetin — but treating them as interchangeable flavonoids misses a distinction that matters directly for skin-brightening and antioxidant formulation work. The reduction that separates the two compounds is a saturation of the C2–C3 double bond in the flavonoid C-ring, which converts myricetin’s flavonol structure into DHM’s flavanonol structure.^[1] That single structural change is the reason the two compounds behave differently enough in formulation-relevant contexts to warrant a real comparison, not just a footnote.

Antioxidant Behavior: Stability vs. a Documented Dual Nature

Both compounds share myricetin’s hallmark pyrogallol-substituted B-ring, the structural feature most responsible for strong radical-scavenging and iron-chelating activity in this compound family. But myricetin itself has a well-documented dual nature that formulators should know about: published research on myricetin’s redox chemistry found that it behaves as a genuine antioxidant in the presence of ascorbic acid, but shifts toward pro-oxidant activity — generating reactive oxygen species via iron reduction — under ascorbic-acid-free conditions, producing a U-shaped dose-response curve rather than a simple “more is better” antioxidant profile.^[2] This is not a flaw specific to poor-quality myricetin material — it is documented chemistry inherent to the parent compound’s structure, and it means myricetin’s antioxidant behavior in a finished formulation depends meaningfully on what else is in that formulation.

DHM’s antioxidant mechanism has been separately characterized via DPPH radical scavenging and lipid peroxidation inhibition assays, with iron-chelating activity identified as a contributing mechanism — research we cover in full, alongside DHM’s complete specification data, on our DHM product page. We are not aware of a published study directly comparing DHM and myricetin’s pro-oxidant potential side by side under identical conditions, so this should not be read as a claim that DHM is free of any comparable behavior — only that the specific dual-nature chemistry documented for myricetin has not been established for DHM in the same way. Formulators working with either compound in an oxidation-sensitive matrix should request stability data specific to their formulation system rather than assuming antioxidant behavior transfers cleanly from an isolated lab assay to a finished product.

Skin-Brightening: Where the Real Formulation Choice Shows Up

Flavonols as a class are generally weak direct tyrosinase inhibitors compared to purpose-built inhibitors like kojic acid — a comprehensive review of tyrosinase inhibitors found that even quercetin, among the more active flavonols tested, produced only modest direct enzyme inhibition relative to standard whitening actives.^[3] This matters because it reframes what “skin-brightening flavonoid” actually means in practice: for compounds in this family, meaningful anti-melanogenic activity in cell studies often comes from downregulating the signaling pathways and proteins that drive melanin production (MITF, tyrosinase-related proteins, and the upstream MAPK/PKA/PKC pathways that control them) rather than from directly blocking the tyrosinase enzyme itself.

This is precisely the mechanism documented for DHM specifically — published research in B16F10 melanoma cells found DHM suppressed intracellular tyrosinase activity and reduced melanin content by downregulating MC1R, MITF, and TRP-1 expression via inhibition of MAPK, PKA, and PKC signaling, alongside reducing intracellular reactive oxygen species. Full detail on that mechanism study is covered on our product page rather than repeated here. Myricetin and its glycoside derivatives have separately been studied in the same B16F10 cell-signaling framework — for example, myricetin 3-O-galactoside was found to suppress melanogenesis in α-MSH-stimulated B16F10 cells via PKA and ERK1/2 pathway regulation, a related but distinct signaling route from the MAPK/PKA/PKC pathway documented for DHM.^[4] The practical takeaway for formulators: both compounds have genuine, published anti-melanogenic research behind them, but the specific pathway evidence is compound-specific — a brightening claim substantiated for DHM should not be assumed to transfer automatically to myricetin, or to a different myricetin derivative, without its own supporting citation.

Solubility: A Real, Measurable Formulation Difference

Beyond the mechanism-level comparisons above, there is a concrete physical property difference worth flagging for formulators specifically: myricetin’s water solubility has been measured at under 5 μg/mL across all four of its known crystalline forms, in a dedicated solid-state and solution characterization study.^[5] That is markedly lower than DHM’s water solubility of roughly 0.2 mg/mL (200 μg/mL) at room temperature — DHM’s saturated C-ring appears to make it meaningfully easier to work with in aqueous-adjacent formulation contexts than myricetin, even though neither compound is what most formulators would call water-soluble in an absolute sense. This is a practical, testable reason DHM tends to be the more workable choice when an aqueous or semi-aqueous delivery system is part of the formulation brief, independent of which compound’s research base is more complete.

Choosing Between Them for a Formulation

In practice, the choice comes down to what your formulation and claim strategy actually need. DHM has the more complete published research base specifically at the parent-compound level — the melanogenesis and antioxidant mechanism studies referenced above were conducted on DHM itself, not a derivative — along with an established commercial supply chain from vine tea at HPLC-verified purity. Myricetin’s own direct research base exists but is smaller at the parent-compound level, with a meaningful share of the more targeted anti-melanogenic findings coming from specific glycoside derivatives rather than myricetin itself. For a formulation that needs a well-documented, single-compound brightening or antioxidant active with a mature supply chain, DHM is generally the more straightforward specification.

Valeherb sources dihydromyricetin exclusively from vine tea (Ampelopsis grossedentata), standardized to 98% purity by HPLC. Full specifications, research background, and formulation guidance are available on our bulk dihydromyricetin powder product page. For background on DHM’s chemistry and natural sourcing, see our companion article, What Is Dihydromyricetin? Chemistry, Natural Sources, and How It’s Made.

Frequently Asked Questions

References